Reading room

Pathway comparisons.

Compare biological targets without turning separate clinical studies into a misleading leaderboard. These guides distinguish metabolic receptor families and growth-hormone-axis mechanisms, then show which differences in study design matter to the interpretation.

Reset filters

Guides in this topic

1–12 of 15 guides

Page 1 of 2
Amycretin and zenagamtide name cards beside GLP-1, amylin and calcitonin research tabs in a classified archive.Peptide Fundamentals

Amycretin (Zenagamtide): What the New Trials Actually Show

Amycretin, now also reported as zenagamtide, is an engineered molecule with GLP-1 and amylin receptor activity.

Updated 2026-10-29 ↗
Paired Cagrilintide and Semaglutide evidence packet held in a single CagriSema archive sleeve, with a physically Semaglutide comparator sleeve, in the CagriSema vs Semaglutide research file.Research Practice

CagriSema vs Semaglutide: How to Read Combination Evidence

CagriSema research tests coadministered cagrilintide and semaglutide, not a new name for semaglutide alone.

Updated 2026-10-29 ↗
Three-object evidence arrangement of a glucose-analysis vessel, a mechanical body-weight scale photograph and a liver teaching model, in the Cotadutide research file.Research Practice

Cotadutide: Glucose, Weight and Liver Findings Explained

Cotadutide research combines a GLP-1/glucagon receptor design with clinical measurements of glucose, weight and hepatic markers.

Updated 2026-10-29 ↗
Close-up research assay plate with cAMP and Other readouts document tabs in a GLP-1 signaling dossier, in the Ecnoglutide research file.Research Practice

Ecnoglutide: What cAMP-Biased GLP-1 Signaling Means

Ecnoglutide is described as a cAMP-biased GLP-1 receptor agonist. That is a statement about signaling in an assay, not a clinical verdict that the molecule works better than all other GLP-1 medicines.

Updated 2026-10-29 ↗
Eloralintide research file with an assay plate, amylin index slip and a 48-week follow-up register.Research Practice

Eloralintide: Selective Amylin Design and the 48-Week Trial

Eloralintide research links a molecular design question with a human weight-management question.

Updated 2026-10-29 ↗
Y-shaped antibody teaching model with two separately boxed peptide sample tags on an opened evidence tray, in the MariTide research file.Research Practice

MariTide: Why a Peptide–Antibody Conjugate Is a Different Design

MariTide, or maridebart cafraglutide, combines a peptide component with an antibody-based design. That architecture helps explain why it belongs in a discussion of metabolic peptides while differing from a standalone peptide analogue.

Updated 2026-10-29 ↗
Small-molecule identity research container and an archived peptide reference strip, separate, under a GLP-1 target index tab, in the Orforglipron research file.Peptide Fundamentals

Orforglipron: Why a GLP-1 Drug Does Not Have to Be a Peptide

Orforglipron activates the GLP-1 receptor, but it is a small molecule rather than a peptide. That distinction is useful because online discussions often use GLP-1, injectable and peptide as if they were the same classification.

Updated 2026-10-29 ↗
Detailed liver teaching specimen with distinct histology-category archives Liver fat, Inflammation, Fibrosis, in the Pemvidutide and MASH research file.Research Practice

Pemvidutide and MASH: Liver Endpoints Beyond Weight Loss

Pemvidutide’s IMPACT report separates two liver-biopsy questions: MASH resolution without worsening fibrosis and fibrosis improvement without worsening MASH.

Updated 2026-10-29 ↗
Petrelintide amylin-analogue identity card and study-protocol envelopes under a magnifier focused on endpoint definitions.Research Practice

Petrelintide: Reading the New Amylin Research

Petrelintide is a long-acting amylin analogue being investigated through molecular-design and human clinical studies.

Updated 2026-10-29 ↗
Three-compartment target-system archive tray GIP, GLP-1, GCGR for Retatrutide and a two-compartment GIP, GLP-1 tray for Tirzepatide, in the Retatrutide vs Tirzepatide research file.Research Practice

Retatrutide vs Tirzepatide: Receptors, Trials and Fair Comparisons

Retatrutide and tirzepatide differ in receptor-related design and in the clinical programs available for comparison.

Updated 2026-10-29 ↗
Two study-intervention packets Semaglutide and Tirzepatide inside a single shared head-to-head trial binder, a heavy binder clamp visually unites them, in the Semaglutide vs Tirzepatide research file.Research Practice

Semaglutide vs Tirzepatide: What Head-to-Head Evidence Shows

SURMOUNT-5 directly compared tirzepatide with semaglutide for weight management in adults with obesity without type 2 diabetes.

Updated 2026-10-29 ↗
Empty capsule specimen holder and a sealed injection-formulation archive tray, each attached to an independent study packet, in the VK2735 research file.Research Practice

VK2735: Reading VENTURE and the Oral Research Separately

VK2735 has been studied as an injected and an oral GIP/GLP-1 receptor agonist, but the two research records should not be fused into one result.

Updated 2026-10-29 ↗

Explore the related peptide dossiers

Peptide Pathways: Receptors & Mechanisms Compared | PeptideTwo